KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Other Non Operating Income (2016 - 2023)

Historic Other Non Operating Income for TherapeuticsMD (TXMD) over the last 12 years, with Q3 2023 value amounting to $359000.0.

  • TherapeuticsMD's Other Non Operating Income rose 42053.57% to $359000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $880000.0, marking a year-over-year increase of 11035.29%. This contributed to the annual value of -$117000.0 for FY2022, which is 14301.47% down from last year.
  • According to the latest figures from Q3 2023, TherapeuticsMD's Other Non Operating Income is $359000.0, which was up 42053.57% from $103000.0 recorded in Q2 2023.
  • In the past 5 years, TherapeuticsMD's Other Non Operating Income ranged from a high of $703662.0 in Q3 2019 and a low of -$10.1 million during Q2 2019
  • Its 5-year average for Other Non Operating Income is -$813999.2, with a median of $89000.0 in 2020.
  • Per our database at Business Quant, TherapeuticsMD's Other Non Operating Income surged by 3596956.52% in 2020 and then tumbled by 696885.25% in 2022.
  • Over the past 5 years, TherapeuticsMD's Other Non Operating Income (Quarter) stood at -$368.0 in 2019, then surged by 35969.57% to $132000.0 in 2020, then plummeted by 93.94% to $8000.0 in 2021, then surged by 37.5% to $11000.0 in 2022, then soared by 3163.64% to $359000.0 in 2023.
  • Its last three reported values are $359000.0 in Q3 2023, $103000.0 for Q2 2023, and $407000.0 during Q1 2023.